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Abstract 
Background: The release of the results of the oestrogen plus progesterone therapy (EPT) arm of the Women’s Health Initiative 
(WHI) in July 2002 started a worldwide process of reconsideration of the rationale behind hormone therapy (HT). This process was 
accelerated after the release of the results from the oestrogen-only (ET) arm of the same study. The results of the WHI reinforced 
the indications of HT to alleviate vasomotor symptoms and to prevent bone loss associated with early menopause, but refuted the 
possibility of cardioprotective effects and raised uncertainty around the risk of breast cancer for long-term users. In response, new 
guidelines and position statements were developed to aid healthcare practitioners and patients in various countries, including South 
Africa. The dissemination and penetration of all this information has been assessed in a number of countries, but the extent of its 
effect on the South African market is as yet unknown. Accordingly, the aim of this study was to assess the use of HT in the South 
African private sector from 2001 to 2005.
Methods: Monthly HT sales data for January 2001 to October 2005 were obtained from IMS Health (SA). Three successive periods 
were compared: (1) January 2001 to June 2002 (discontinuation of the WHI oestrogen plus progestogen arm), (2) July 2002 to 
February 2004 (termination of the WHI oestrogen only arm) and (3) March 2004 to October 2005. 
Results: Overall, sales of HT fell 6.9% between periods 1 and 2 and 14.6% between periods 2 and 3. The total sales of ET 
predominated; they were more than double those of EPT. For ET, the sale of conjugated equine oestrogen (CEE) preparations exceeded 
those of non-CEE ET preparations, while for EPT preparations the reverse was true. The decline in ET sales was mostly accounted for 
by the fall in sales of CEE, by 9.8% and 20.6% for the two periods respectively. There was an increase in sales of both low-dose CEE 
and non-CEE, although the magnitude of increase in the case of the latter was much greater. Throughout the entire study period, CEE 
0.625 mg tablets were found to account for the greatest sales volumes. Private sector sales represented 74.4% of total national HT 
sales over this period.
Conclusion: The release of the WHI findings resulted in a modest decrease in HT sales in South Africa, although it was less dramatic 
than sales reported elsewhere. The change in prescribing cannot be attributed to any single factor. Factors such as publicity, 
adherence to new guidelines, and pharmaceutical marketing may all have contributed. Guidelines need to be updated as the results 
of new research continue to be published. There is also a need to periodically review prescribing trends, and to assess compliance 
with evidence-based guidelines, in order to improve the quality of medicines use. The majority of prescriptions for HT in South Africa 
are written by general practitioners, rather than by specialists. It is thus imperative that guidelines be appropriately framed for this 
market, as well as interpreted and applied.
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Background
Globally, the release of results from the oestrogen plus progesterone 
therapy (EPT) arm of the Women’s Health Initiative (WHI) in July 
2002 marked the start of a process of reconsideration of the rationale 
behind hormone therapy (HT).1,2 This process was accelerated after 
the release of the results from the oestrogen-only (ET) arm of the 
same study.3 The results of the WHI reinforced the indications of HT 
to alleviate vasomotor symptoms and to prevent bone loss associated 
with early menopause, but refuted the possibility of cardioprotective 
effects and raised uncertainty around the risk of breast cancer for 
long-term users. In response, new guidelines and position statements 
were developed to aid healthcare practitioners and patients in various 
countries, including South Africa.4
The extent of the reaction to this new evidence, from a large 
randomised controlled trial rather than observational studies, can be 
gauged by the speed with which guidelines were produced. The South 
African Menopause Society guidelines were published only five months 
after the release of the results from the WHI ET arm. 
The WHI results received wide publicity in both the lay press and 
medical literature. Any changes in sales of HT products, which are 
obtainable only by prescription, would thus result from a combination 
of changes in patient demand, prescriber attitudes, adherence 
to published guidelines, and also ongoing marketing efforts by 
pharmaceutical manufacturers. The dissemination and penetration of 
all this information has been assessed in a number of countries, but 
the extent of its effect on the South African market is as yet unknown. 
Accordingly, the aim of this study was to assess the use of HT in the 
South African private sector from 2001 to 2005.
Methods
This study was approved by the Research Ethics Committee, Nelson R 
Mandela School of Medicine, Durban, South Africa (Ref: E201/05).
Data were obtained from the IMS Health (SA) pharmaceutical market 
measurements database. IMS Health (SA) is an independent company 
that collects monthly data as electronic downloads of pharmaceutical 
sales to retail pharmacies, dispensing medical practitioners and 
private hospitals. Total private sector monthly sales of ET, EPT and 
progestogen-only preparations (PT) products for the management of 
menopause were collected for the period January 2001 to October 
2005. Data were individually presented for each formulation, strength 
and pack size. Sales of oral solid dosage forms were thus expressed 
as the total number of dosage units (“pills”), while those of other 
formulations, such as creams and patches, were recorded as sales 
units. 
Data were presented graphically as total sales per quarter. Sales in 
three successive periods were compared: (1) January 2001 to June 
2002 (corresponding with the discontinuation of the WHI EPT arm); (2) 
July 2002 to February 2004 (corresponding with the early termination 
of the WHI ET arm); and (3) March 2004 to October 2005. Within each 
period, data were presented as mean monthly sales per period. Mean 
monthly sales for each period were calculated using the total sales 
and the number of months in that particular period. The mean monthly 
sales in each period were compared by expressing the difference in 
sales, as a percentage of the mean of sales in the preceding period. 
As total national sales figures for the private sector were used, not 
merely a sample thereof, no confidence intervals or other measures of 
variability were computed.
Results
Private sector sales of the oral solid dosage forms for the entire study 
period are shown in Figure 1. The total sales of ET predominated; they 
were more than double those of EPT. For ET, the sale of conjugated 
equine oestrogen (CEE) preparations exceeded those of non-CEE ET 
preparations, while for EPT preparations the reverse was true.
Overall sales of HT fell by 6.9% between periods 1 and 2 and 14.6% 
between periods 2 and 3. Over the entire study period, all sales 
declined except those of non-CEE ET preparations. 
Sales of ET fell by 4.7% and 12.3% between periods 1 and 2 and 
periods 2 and 3, respectively. The decline in 
ET sales was accounted for by the decrease 
in CEE ET preparations (9.8% and 20.6%, 
respectively). In fact, sales of non-CEE ET 
preparations actually rose by 5.6% and 2.2% 
for the two periods, respectively. 
Sales of EPT declined by 10.3% and 15.5% 
between periods 1 and 2 and periods 2 and 
3, respectively. The decline in sales of CEE 
EPT preparations was greater than the decline 
in sales of non-CEE EPT preparations. For 
period 1 to 2, sales of CEE EPT preparations 
fell by 21.9% compared to only 6.3% for 
non-CEE EPT preparations. The decreases 
from period 2 to 3 were 35.8% and 9.7%, 
respectively.
While falling gradually during the study period, 
sales of PT remained consistently low.
Table I shows the mean sales in each of the 
three periods for the dominant form of oral HT, 
Figure I:  Total Sales per Quarter of Oral Hormone Therapy in the South African 
Private Sector, 2001-2005
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disaggregated by the type of oestrogen (CEE and 17β oestradiol) and 
strength, together with sales of vaginal and transdermal formulations. 
Table I:  Mean of monthly sales of selected strengths and formulations of 
oestrogen therapy (ET) for the periods 1, 2 and 3
PERIOD 1 PERIOD 2 PERIOD 3
Oral Oestrogen Pills (x1000) Pills (x1000) Pills (x1000)
Conjugated equine oestrogens
0.3 mg 189 208 268
0.625 mg 1871 1699 1351
1.25 mg 933 837 559
2.5 mg 48 0 0
Micronised 17β oestradiol
1 mg 12 153 345
2 mg 613 589 492
4 mg 239 230 203
Other Oestrogen 
Formulations Units (x1000) Units (x1000) Units (x1000)
 Vaginal preparations 8 8 9
Transdermal patches 29 26 23
Throughout the entire study period, CEE 0.625 mg tablets were found 
to account for the greatest sales volumes. The highest strength CEE 
formulation (2.5 mg) was removed from the market in April 2002. 
The sales of CEE 1.25 mg, though declining,, remained relatively 
high. However, they declined more than those of the equipotent 17β 
oestradiol strength (4 mg); they declined by 10.3%, compared to 3.8% 
for period 1 to 2, and by 33.2%, compared to 11.7% for period 2 to 
3. Similarly, sales of CEE 0.625 mg declined more than those of the 
equipotent 17β oestradiol strength (2 mg). Between periods 1 and 2 
the declines were 9.2% and 3.9% respectively, while for periods 2 to 
3 they were 20.5% and 16.4%, respectively. In contrast, there was an 
increase in sales of both low-dose CEE (0.3 mg) and 17β oestradiol 
(1 mg). Of particular interest is the magnitude of the increase in sales 
of low-dose 17β oestradiol. While sales of CEE 0.3 mg increased by 
9.8 and 29% from periods 1 to 2 and periods 2 to 3, respectively, the 
corresponding increases in sales of 17β oestradiol 1 mg were 1211.6% 
and 125.3%.
Sales of vaginal preparations were small, and increased only 
slightly (12.2% from period 2 to 3, and 13.4% overall), while sales of 
oestrogen-only transdermal preparations declined gradually.
Discussion
South Africa’s private health sector predominantly serves a highly 
urbanised and relatively affluent sub-population, which enjoys easy 
access to various media. The sales figures captured by IMS Health 
would therefore represent, in the main, prescriptions issued to 
peri- and post-menopausal women from the almost 7 million insured 
population (about 15% of the total population).5 HT use in this highly 
selected sub-population is expected to be high. Private sector sales 
represented 74.4% of total national HT sales over this period. A survey 
among a sample of 398 post-menopausal women seen at a single 
specialist private practice in Cape Town, South Africa, showed that, 
as at July 2003, 78.6% were using HT.6 A similar survey by the same 
group in 2004 showed that 78.5% of the women were using HT.7 Other 
developing and middle-income countries have similar elite populations, 
served by the private healthcare sector. Data from Chile showed 
that, after the release of the first WHI report, 67.3% of a sample of 
women aged 40 to 64 years, living in an exclusive residential area and 
receiving private health care, were using HT and 47.3% were aware of 
the WHI study.8 
Reaction to the WHI results in other countries has been marked, if 
variable. Comparisons of findings between different countries are 
not straightforward. Some studies are population based while others 
are drawn from selected sub-populations. The time periods surveyed 
also vary. We found a modest reduction (6.9%) in total private sector 
HT sales after the release of results from the EPT arm of the WHI, 
and a further decline (14.6%) after the release of results from the ET 
arm. The reaction in both the United States of America (USA) and 
United Kingdom (UK) was far more marked, showing reductions of 
38% and 20.7% when the EPT arm was discontinued.9,10 The UK 
response was, however, characterised by the authors as “limited”, 
in comparison to that seen in the USA. Based on a random national 
sample, another USA survey showed that use of HT had decreased 
57% from the first half of 2002 to the first half of 2004; from 28% of the 
sample to 12%.11 This survey would however not have captured the 
full impact of the WHI ET results. The extent of exposure to the WHI 
results, after the discontinuation of the EPT arm, has been assessed 
in a USA setting.12 Of a sample of HT users, 93% reported knowing 
about the WHI and 56% had reported attempting to discontinue HT 
in the 6 to 8 months after July 2002. In Australia, where in 2004 the 
ever use of HT in women aged 50 years and older was reported 
to be 46.5% (with a mean duration of use of 7.46 years),13 current 
use dropped from 28% in 2000 to 10.2% in 2002 (a fall of 64%), but 
returned to 18.8% in 2003.14 The media was shown to have had the 
main influence on women’s decision making. It was also noted that 
half of those who restarted therapy changed to another type of HT.14 
In the Netherlands, by contrast, a more marked decline in use of EPT 
was seen after the publication of the observational Million Women 
Study15 than after the release of the WHI EPT arm results.16 A follow-up 
study in the Netherlands showed a 66% reduction in EPT use among 
women aged 47–74 years between 2001 and 2004.17 Prevalence 
of HT use in this age group was, however, markedly lower than in 
other countries, at 5.64% and 2.39% in 2001 and 2004, respectively. 
According to Townsend and Nanchahal, even after taking into account 
the 21% reduction in HT use seen in the UK after 2001 (from an 
estimated baseline prevalence of 36% of postmenopausal women), 
HT would be still be “unprecedented as a drug in widespread use by a 
predominantly well population”.10 
Differences in the relative use of EPT and ET are also striking. In 
both our study and in the US, use of unopposed oestrogen products 
dominated. The same has been shown in Hong Kong.18 The reverse 
was true in the UK and the Netherlands. The appropriateness of 
unopposed HT use needs to be carefully reviewed by all healthcare 
practitioners at every opportunity.
Differences in the use of CEE and non-CEE HT preparations also 
point to how the results of the WHI study (and the Million Women 
study) have been interpreted and applied. Although the Hong Kong 
data showed a 43.5% decline in CEE EPT public sector prescriptions 
from the first to the second half of 2002, the usage trend was already 
negative. Prescriptions for CEE ET preparations in Hong Kong fell by 
22.4% over the same period. Overall, HT use stabilised in Hong Kong 
in 2003. In the USA, CEE preparations accounted for most of the ET 
and EPT sales, while the opposite was true in the UK. In our study, 
sales of CEE ET preparations exceeded those of other products, while 
for EPT preparations the reverse was the case. Despite the fact that 
the initial WHI report involved EPT only, our study showed that ET 
sales also fell by 4.7% after the EPT arm was stopped. This trend was 
also observed in the USA, although there the decline was much larger. 
These declines, in both countries, may have been partly due to the fact 
that some women were getting their opposed HT in the form of two 
Original Research
SA Fam Pract 2008                  Vol 50 No 642c
medicines rather than a combination formulation. This possibility is, to 
some extent, supported by the reduction observed in the sales of PT. 
On the other hand it is possible that women taking ET only, and their 
healthcare practitioners, were extrapolating the findings from the EPT 
arm of the study, to a possibility of harm with ET. Indeed, in January 
2003 the FDA ordered black box warnings to be placed on the labels of 
all drugs for menopausal symptoms containing oestrogen or oestrogen 
and progestogen. Not unexpectedly, we observed a larger fall in ET 
sales once the ET arm of the WHI was stopped (12.3%). 
That the greater decline in sales was seen with CEE preparations 
is also consistent with findings in the UK and USA, and is probably 
related to the fact that the WHI study involved the use of these 
products specifically, and therefore, they were perceived as most 
directly linked with the evidence of harm. In addition, changes in 
marketing activity may be responsible for some of the changes seen. 
In the quarter before the release of the WHI EPT results, promotional 
spending on HT in the USA was shown to be        $71 million, or $350 
per USA physician.19 This decreased by 37% after the release of the 
WHI EPT results. The greatest decline in promotional spending was 
associated with the 0.625 mg CEE EPT product. A 100% decrease 
in direct-to-consumer advertising spending was seen. Importantly, 
this study also showed a “resurgence” in promotional spending on 
low-dose EPT and a modest increase in prescriptions for this type of 
HT towards the end of 2003. USA data also showed that sales of 0.3 
mg CEE grew by 6% in the second half of 2002. While we have no 
access to data that show even a temporal association with promotional 
spending in South Africa, the marked increases in sales of low-dose 
HT products, especially non-CEE preparations, are noteworthy. This 
may partly be explained by the inclusion in local and international 
guidelines of recommendations that lower than standard dose products 
should be used if effective.4,20 In the Hong Kong study, the use of low 
dose ET doubled between the first half of 2002 and the second half of 
2004.18 
The slight changes in the low sales of vaginal preparations over the 
entire study period in South Africa are not markedly different from 
those seen elsewhere. In the Netherlands, for example, the prevalence 
of the use of low-potency vaginal oestrogens did not change between 
2001 and 2004.17 The slow decline in sales of transdermal preparations 
seen in our study also mirrors that seen in the US, but is less than 
that seen in the Netherlands. Although new evidence has raised the 
possibility that transdermal administration may not be associated with 
increased risk of venous thromboembolism, it has shown that the use 
of 17β oestradiol products is associated with increased risk.21 
Data from the ESTHER study have raised the possibility that the 
type of HT (particularly the type of progestogen) and the route of 
administration may influence the risk benefit profile.21 Acknowledging 
the new data, in relation to venous thromboembolism risk, Rexrode 
and Manson22 nonetheless highlighted the need for further research on 
this issue.
Increased use of low-dose HT products would seem to be in line with 
published guidelines. However, although sales of the higher doses 
of ET in South AFrica decreased over the study period, the reduction 
was considerably smaller than that seen in other countries. While 
direct-to-consumer advertising is not allowed in South Africa, this 
cannot account for the differences seen, as Europe and Australia also 
prohibit such practices. While no data exist to show how well the lay 
press covered the WHI study, a clear guideline from the South African 
Menopause Society was quickly published in a local medical journal. 
That a modest change is seen in prescribing behaviour, even after 
the release of important new data, has been shown before, in relation 
to alpha-blocker use after the publication of the ALLHAT study.23 The 
dissemination of written material only is recognised as a poor way 
to improve the rationality of medicines use.24 Naylor has attempted 
to analyse the differences in response in the USA to the WHI and 
ALLHAT results, and has identified pharmaceutical marketing as one of 
the more powerful forces at work.25 
The present study was subject to various limitations. Although 
responsible for the majority of national HT sales, the private healthcare 
sector serves a highly selected sub-population. In addition, sales 
data lack information related to the patient, such as age, presence 
or absence of a uterus, and co-morbidities. No information can 
be obtained about the number of repeat prescriptions, duration of 
use, switching between dosages and formulations, or reasons for 
discontinuing therapy.
Conclusions
The release of the WHI findings in 2002 resulted in a decline in HT 
sales in South Africa, but it has been much less dramatic than reported 
elsewhere. More recent secondary analyses of the WHI data have 
raised the possibility that women who started HT closer to menopause 
tended to have a reduced risk of coronary heart disease compared 
with women who started HT later.26 This appears to confirm the results 
of previous meta-analyses.27,28 Nonetheless, Grady and Barrett-
Connor provided a succinct bottom line based on available data: 
“treat bothersome menopausal symptoms with the lowest effective 
dose of HT for the shortest time possible and do not use it to prevent 
disease “.29 Attributing the observed changes in prescribing behaviour 
to any one factor is not possible in view of the complexities involved. 
Although publicity, both in the lay and professional press may have 
had some effect, a certain degree of adherence to new guidelines 
and awareness of labelling changes made in other countries, notably 
the USA, may also have impacted on either prescriber or patient 
behaviour. In addition, the impact of marketing by pharmaceutical 
manufacturers cannot be discounted. Guidelines need to be updated 
as the results of new research become available. There is also a need 
to periodically review prescribing trends, and to assess compliance 
with evidence-based guidelines, in order to improve the quality of 
medicines use. Finally there is some evidence from IMS Health SA 
(Personal communication: IMS Health SA, based on the National 
Disease and Therapeutic Index stratified sample of health practitioners 
in South Africa.) that the majority of prescriptions for HT in South Africa 
are written by general practitioners rather than by specialists. It is thus 
imperative that guidelines be appropriately framed for this market, as 
well as adequately interpreted and applied.
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